News | June 15, 2024
Jubilant Pharmova announces voluntary prepayment of US$ 75 million term loan
As on 31st March 2024, Jubilant Pharmova Limited reported Gross Debt at Rs. 3,414 crore
As on 31st March 2024, Jubilant Pharmova Limited reported Gross Debt at Rs. 3,414 crore
Over 13 million US adults aged 50-59 years have a medical condition that increases their risk of severe RSV outcomes
Co-founder and previous CEO Lowry Curley becomes Chief Scientific Officer
Sapala has a strong customer base including innovator Pharma, CDMOs & diagnostic companies
The primary endpoint in the final analysis was assessed by change in the North Star Ambulatory Assessment at one year after treatment
his strategic collaboration with BluSim Tech marks a significant milestone in Fischer MVL's journey towards expanding its healthcare portfolio
The Gavi Board today approved the Vaccine Alliance's strategy for the five-year period running from 2026 to 2030
This strategic decision will unlock significant value for our scientific and industrial products business
DCGI has also granted permission to manufacture and market FDF of Cefepime and Enmetazobactam as a dry powder injectable
PICCOLO trial met its primary endpoint of objective response rate (ORR)
Subscribe To Our Newsletter & Stay Updated
